Ultomiris
| Chemical Name | ravulizumab |
| Dosage Form | Injection (intravenous; 300 mg/30 mL) |
| Drug Class | Monoclonal antibodies |
| System | Blood |
| Company | Alexion Pharmaceuticals Inc. |
| Approval Year | 2018 |
Indication
- To treat paroxysmal nocturnal hemoglobinuria in adults. •
- To treat atypical hemolytic uremic syndrome in patients ≥ 1 month of age.